Oscar Health target cut to $45 at Piper Sandler despite Q3 beat
As seen on the 24/7 Wall St. homepage on November 6, 2026.
A $3 target trim right after a beat and raise, with the Overweight rating intact, says Piper Sandler is marking 2027 ACA pricing risk rather than anything in the quarter.
Oscar Health $OSCR price target lowered to $45 from $48 at Piper Sandler Piper Sandler lowered the firm's price target on Oscar Health to $45 from $48 and keeps an Overweight rating on the shares following the Q3 beat and raise. The firm notes the company clarified the 2027 https://t.co/Y9qYWDaANV
- Replies0
- Reposts2
- Likes25
Continue ReadingShow less
Piper Sandler trimmed its price target on Oscar Health to $45 while holding its Overweight rating intact. The move came directly after Oscar posted a Q3 beat and raise, meaning the analyst is not pulling back on the bull case for the business.
The target cut points to what lies ahead. The firm noted that Oscar clarified its 2027 outlook, and the reduction in the target appears to reflect how Piper Sandler is pricing risk around 2027 ACA dynamics rather than any disappointment in the current quarter.
Sponsored
The analyst still expects the stock to outperform but is recalibrating the ceiling to account for a more uncertain regulatory and pricing environment heading into 2027.
For investors already in the name, the Q3 beat and raise is the near-term anchor. The key thing to track now is how Oscar's 2027 guidance commentary develops as more details emerge, since that is the variable Piper Sandler flagged as the reason for the adjustment.
Mentioned: OSCR